Insider Selling: Juno Therapeutics Inc (JUNO) CFO Sells $391,650.00 in Stock
Juno Therapeutics Inc (NASDAQ:JUNO) CFO Steve Harr sold 8,750 shares of the company’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $391,650.00. Following the completion of the transaction, the chief financial officer now owns 772,082 shares in the company, valued at $34,558,390.32. The sale was disclosed in a filing with the SEC, which is available through this link.
Shares of Juno Therapeutics Inc (JUNO) opened at $46.00 on Monday. Juno Therapeutics Inc has a 52-week low of $18.03 and a 52-week high of $63.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77. The company has a market cap of $5,141.21, a P/E ratio of -13.61 and a beta of 2.33.
Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The company had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter in the prior year, the company posted ($0.57) earnings per share. Juno Therapeutics’s revenue for the quarter was up 115.4% compared to the same quarter last year. equities analysts forecast that Juno Therapeutics Inc will post -4.02 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company lifted its position in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in Juno Therapeutics during the second quarter valued at approximately $105,000. Advisor Group Inc. lifted its position in Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,439 shares during the last quarter. QS Investors LLC purchased a new stake in Juno Therapeutics during the second quarter valued at approximately $135,000. Finally, Bronfman E.L. Rothschild L.P. lifted its position in Juno Therapeutics by 27,376.9% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 3,559 shares during the last quarter. 69.94% of the stock is owned by institutional investors.
A number of equities analysts have commented on JUNO shares. Wedbush upgraded shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 target price on the stock in a research note on Tuesday, August 29th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $54.00 price target (up previously from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. Raymond James Financial upped their price target on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $44.00 price target on shares of Juno Therapeutics in a research report on Friday, October 6th. Finally, Standpoint Research reaffirmed a “reduce” rating on shares of Juno Therapeutics in a research report on Thursday, August 31st. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $45.48.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.